{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:09:40Z","timestamp":1783948180646,"version":"3.55.0"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Selective cyclooxygenase-2 (COX-2) inhibitors are often considered when anti-inflammatory analgesia is needed for musculoskeletal pain in patients with inflammatory bowel disease (IBD), but concerns remain about intestinal safety. The clinical evidence on short-term selective COX-2 inhibitor use in IBD, with focus on disease activity outcomes, was reviewed. A prespecified literature search was performed in PubMed and the Cochrane Library supplemented by reference list screening. Clinical trials and clinical studies evaluating celecoxib, etoricoxib or rofecoxib in patients with IBD and musculoskeletal\/rheumatological symptoms were considered when gastrointestinal (GI) outcomes were reported. Two placebo-controlled randomised trials did not show higher rates of IBD relapse or symptom aggravation vs placebo during short-term treatment in selected patients, including ulcerative colitis in remission and IBD with rheumatic manifestations. Open-label studies and retrospective series reported variable GI adverse events and occasional symptom worsening, but study populations, baseline disease activity, relapse definitions and follow-up duration differed widely. Overall, the strongest available evidence supports cautious short-term use of selective COX-2 inhibitors in selected patients with IBD in remission when anti-inflammatory analgesia is required. Given the small evidence base and limited follow-up, treatment should be time-limited, use the lowest effective dose and include clinical monitoring.<\/jats:p>","DOI":"10.1136\/bmjgast-2026-002316","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:35:13Z","timestamp":1783946113000},"page":"e002316","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Selective COX-2 inhibitors for short-term musculoskeletal pain in inflammatory bowel disease in remission: a narrative review"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-2308","authenticated-orcid":false,"given":"Michiel A","family":"van Nieuwenhoven","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, Department of Internal Medicine, Division of Gastroenterology, \u00d6rebro University, \u00d6rebro, Sweden"},{"name":"Faculty of Medicine and Health, University Health Care Research Unit, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2026071305350557000_13.1.e002316.1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00004.2008"},{"key":"2026071305350557000_13.1.e002316.2","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/apt.14606","article-title":"Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn\u2019s disease and ulcerative colitis exacerbation","volume":"47","author":"Moninuola","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026071305350557000_13.1.e002316.3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad108"},{"key":"2026071305350557000_13.1.e002316.4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.14309\/ajg.0000000000001932","article-title":"The Association Between Nonsteroidal Anti-Inflammatory Drug Use and Inflammatory Bowel Disease Exacerbations: A True Association or Residual Bias?","volume":"117","author":"Cohen-Mekelburg","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026071305350557000_13.1.e002316.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"2026071305350557000_13.1.e002316.6","article-title":"Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease","volume":"2014","author":"Miao","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071305350557000_13.1.e002316.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.12.002"},{"key":"2026071305350557000_13.1.e002316.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00384.x"},{"key":"2026071305350557000_13.1.e002316.9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01596.x"},{"key":"2026071305350557000_13.1.e002316.10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0016-5085(03)00983-1","article-title":"Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease","volume":"125","author":"Biancone","year":"2003","journal-title":"Gastroenterology"},{"key":"2026071305350557000_13.1.e002316.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05608.x"},{"key":"2026071305350557000_13.1.e002316.12","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200407000-00005"},{"key":"2026071305350557000_13.1.e002316.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03730.x"},{"key":"2026071305350557000_13.1.e002316.14","unstructured":"U.S. Food and Drug Administration . Vioxx (rofecoxib) questions and answers. Silver Spring (MD): U.S. Food and Drug Administration; 2016. Available: https:\/\/www.fda.gov\/"},{"key":"2026071305350557000_13.1.e002316.15","unstructured":"U.S. Food and Drug Administration . Celebrex (celecoxib) capsules, for oral use: prescribing information. Silver Spring (MD): U.S. Food and Drug Administration; 2018. Available: https:\/\/www.fda.gov\/"},{"key":"2026071305350557000_13.1.e002316.16","unstructured":"European Medicines Agency . European medicines agency concludes action on cox-2 inhibitors. Amsterdam: European Medicines Agency; 2005. Available: https:\/\/www.ema.europa.eu\/"},{"key":"2026071305350557000_13.1.e002316.17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.36076\/ppj.2015\/18\/599","article-title":"Coxib\u2019s Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis","volume":"18","author":"Ribaldone","year":"2015","journal-title":"Pain Physician"},{"key":"2026071305350557000_13.1.e002316.18","article-title":"S2000\u2003Safety of COX-2 Inhibitor NSAIDs in Inflammatory Bowel Disease: A Propensity-Matched Cohort Study Using Real-World Data","volume":"120","author":"Odah","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026071305350557000_13.1.e002316.19","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-8-7","article-title":"Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data","volume":"8","author":"Levy","year":"2010","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026071305350557000_13.1.e002316.20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/01241398-200311000-00020","article-title":"Use of NSAIDs and COX-2 inhibitors in children with musculoskeletal disorders","volume":"23","author":"Fahey","year":"2003","journal-title":"J Pediatr Orthop"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:35:15Z","timestamp":1783946115000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,13]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjgast-2026-002316"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002316","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}